Join the Non-Small Cell Lung Cancer group to help and get support from people like you.
Non-Small Cell Lung Cancer News
Related terms: Cancer, Lung, Non-Small Cell, Lung Cancer, Non-Small Cell, NSCLC
Lung Cancer Screening Beneficial to Age 80 for Candidates Fit for Surgery
FRIDAY, Sept. 12, 2025 – People aged 75 to 80 years at last screen who are diagnosed with screen-detected lung cancer (LC) have lower overall survival, but those undergoing surgery have no survival...
Many Cancer Patients Say Doctors Aren't Honoring Their Treatment Desires
TUESDAY, Aug. 26, 2025 — Frequently, patients with advanced cancer simply want to be made as comfortable as possible as they wind down their final days. Doctors aren’t listening to their desires, a ne...
FDA Grants Accelerated Approval to Hernexeos (zongertinib) for Previously Treated Patients with HER2-Mutant Advanced NSCLC
Ridgefield, Conn., U.S. and Ingelheim, Germany , August 8, 2025 -- Boehringer Ingelheim’s Hernexeos® (zongertinib tablets) has been approved by the U.S. Food and Drug Administration (FDA). The kinase ...
Increased Intake of Ultraprocessed Food Raises Lung Cancer Risk
THURSDAY, July 31, 2025 – Higher consumption of ultraprocessed foods (UPF) is associated with increased risk of lung cancer, according to a study published online July 29 in Thorax. Kanran Wang,...
'Ultra-Processed' Foods Could Hike Your Odds for Lung Cancer
WEDNESDAY, July 30, 2025 — Experts already know that high consumption of ultra-processed foods is bad news for your health, and new research suggests these foods can raise risks for a major killer: l...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 – The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health...
FDA Grants Accelerated Approval to Zegfrovy (sunvozertinib) for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
July 2, 2025 – Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and D...
Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival
TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says. Corticosteroids are commonly prescribed ...
Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival
TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says. Corticosteroids are commonly prescribed ...
Datroway Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Tokyo and Basking Ridge, NJ – June 23, 2025 – Datroway (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with locally advanced or metastatic EGFR-mutated ...
FDA Approves Ibtrozi (taletrectinib) for Advanced ROS1-Positive Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE) June 11, 2025 – Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the...
American Society of Clinical Oncology, May 31-June 3
The annual meeting of the American Society of Clinical Oncology was held from May 31 to June 3 in Chicago and hosted more than 35,000 participants, including clinicians, academicians, allied health p...
Wildfire Smoke Dents Survival Odds For Lung Cancer Patients
MONDAY, June 2, 2025 — Wildfire smoke could make it harder for people with lung cancer to survive, a new study says. Californians with lung cancer who breathed smoke from wildfires had a 20% i...
FDA Grants Accelerated Approval to Emrelis (telisotuzumab vedotin-tllv) for Non-Small Cell Lung Cancer With High c-Met Protein Overexpression
NORTH CHICAGO, Ill., May 14, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that Emrelis (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Adm...